Mallinckrodt entered into an agreement to acquire US-based Sucampo for US$1.2 B. Sucampo develops drugs targeting high unmet need and its portfolio comprises of an ophthalmology drug, Rescula® (unoprostone isopropyl), and Amitiza® (lubiprostone), which is marketed for constipation and multiple sclerosis. Mallinckrodt would also inherit Sucampo’s two Phase III orphan drugs, VTS-270 and sulindac, to add to its pipeline. The acquisition forms part of Mallinckrodt’s broader strategy to boost revenues to counter declines from its leading drug, Acthar® (adrenocorticotropic hormone), as well as establishing itself as a specialty pharmaceuticals company.